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TRANSPLANTATION OF UNRELATED UMBILICAL CORD BLOOD TO
CORRECT GENETIC DISEASES IN PEDIATRIC PATIENTS
Kurtzberg, J.1; Howrey, R.P.1; Szabolcs, P.M.1; Driscoll, T.A.1; Ciocci,
G.1; Wood, S.1; Stevens, C.E.2; Rubinstein, P.2; Martin, P.L.1 1. Duke
University Medical Center, Durham, NC; 2. New York Blood Center,
New York, NY
Over the past 6 years, 75 patients with genetic diseases have
been transplanted with HLA-mismatched, unrelated umbilical
cord blood (UCB) by the Pediatric BMT Program at Duke Uni-
versity Medical Center. All patients were prepared for transplanta-
tion with chemotherapy-based regimens. 32 patients had inborn
errors of metabolism (20 leukodystrophies including 11 with
Krabbe disease, 12 mucopolysaccharidoses), 6-osteopetrosis, 4-FEL,
b3-Fanconi Anemia, 1- dyskeratosis congenita, 18-immunodefi-
ciency syndromes, 3-β thalassemia, and 3-blackfan diamond ane-
mia. The median patient age was 4.3 years (range 2 weeks-26
years), median weight 15.2kg (range 2-73kg), 61% were male,
23% minority, and 24% were CMV seropositive. 71% of grafts
were mismatched at 2-3 HLA loci. Patients were prepared for
transplant with oral busulfan based regimens and busulfan PK were
obtained in all patients. All patients received ATG pretransplant
and G-CSF post transplant. Prophylaxis for aGvHD was provided
by CSA/steroids. The median cell dose/kg was 6.3x107 /kg,
median CD34 dose 2.3x105 cells/kg and median CD3 dose
9.7x106 cells/kg. Neutrophil engraftment occurred in 97% of
patients in a median of 24 days. The median days to achieve a
platelet count of 50,000/µL and RBC transfusion independence
were 76 and 50, respectively. Moderate to severe aGvHD
occurred in 29% of patients and limited cGvHD occured in 3% of
patients. Twenty-four patients died of infection (25%), toxicity
(65%), or progressive disease (10%). 68% of patients are surviving
event-free for a median of 500 days (range 0.4-6.25 years) as full
chimeras. No patient experienced late graft failure. We conclude
that banked, unrelated UCB provides a readily available source of
donor hematopoietic stem cells for patients with congenital disor-
ders amenable to transplantation therapy. Engraftment can be
obtained without using total body irradiation which limits toxicity,
particularly in young children.
REASSESSMENT OF ABO-INCOMPATIBILITY IN HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Stussi, G.1; Muntwyler, J.1; Seebach, L.1; Passweg, J.2; Schanz, U.1;
Gratwohl, A.2; Gmur, J.1; Seebach, J.1 1. University Hospital Zürich,
Zürich, Switzerland; 2. University Hospital, Basel, Switzerland
Allogeneic hematopoietic stem cell transplantation (HSCT) is
performed routinely across the ABO-barrier. Current concepts
do not stipulate a negative effect of the ABO barrier on survival
and ABO compatible or incompatible transplants are considered
as equivalent. However, this dogma is based on studies per-
formed almost 20 years ago and since then, overall survival and
GvHD rates have clearly improved and reassessment appears
warranted. In order to do so, we performed a retrospective
analysis of 562 consecutive patients receiving HSCT. Among
these, 361 were ABO-identical, 98 had a minor, 86 a major, and
17 a bidirectional incompatibility. As previously reported,
hemolysis occured more frequently in patients with ABO-
incompatibility as compared to ABO identical HSCT (46% vs.
16%, p=0.001) and patients with major or bidirectional ABO-
incompatibility also received more RBC transfusions. In addi-
tion, patients with minor ABO-incompatibility had a higher risk
to develop acute GvHD (odds ratio=3.09, p=0.0024). In con-
trast, the relapse rate was not associated with ABO-compatibili-
ty (p=0.409). Using a multivariate Cox regression analysis
adjusted for potential confounders (disease stage, age, HLA
match, time point of transplantation, GvHD prophylaxis),
patients with bidirectional ABO-incompatibility had a signifi-
cantly higher mortality risk compared to those with ABO-iden-
tity (hazard ratio=2.3, CI 1.28-4.17, p=0.005). In conclusion,
ABO-incompatibility seems to be a significant risk factor after
HSCT. It is associated with a higher incidence of hemolysis.
Even more important is the finding that it may also significantly
affect the incidence of acute GvHD and survival. These data
suggest, that ABO antigens can act as minor histocompatibility
antigens. Although these findings have to be confirmed in larger
prospective studies, the current view that ABO-incompatibility
is irrelevant in HSCT should be reconsidered.
IMMUNE RECONSTITUTION AFTER ALLOGENEIC MARROW VERSUS
BLOOD STEM CELL TRANSPLANTATION
Storek, J.; Dawson, M.A.; Storer, B.; Stevens-Ayers, T.; Maloney, D.G.;
Boeckh, M. Fred Hutchinson Cancer Research Center, Seattle, WA
Allogeneic peripheral blood stem cell grafts contain ~10-times
more T and B cells than marrow grafts. Because these cells may
survive in the recipients long-term, blood stem cell recipients have
been suspected to be less immunocompromised than marrow
recipients. Therefore, we studied the immune reconstitution in
110 patients randomized to allogeneic marrow or ﬁlgrastim-mobi-
lized blood stem cell transplantation. Between day 30 and 365 the
counts of most lymphocyte subsets were higher in the blood stem
cell recipients. The difference was most striking for CD4 Tcells
(~4-fold higher counts for CD45RAhigh CD4 T cells and ~2-fold
higher counts for CD45RAlow/- CD4 T cells, p<0.05). By phyto-
hemagglutinin and herpesvirus antigen-stimulated proliferation,
the T cells appeared equally functional in both patient groups.
Median serum level of total IgG as well as anti-polio IgG was sim-
ilar in both groups. The rate of post-engraftment deﬁnite infec-
tions was 1.6-fold higher in marrow recipients (p=0.006). The rate
of severe (inpatient) post-engraftment deﬁnite infections was 2.0-
fold higher in marrow recipients (p=0.01). The difference in the
rates of deﬁnite infections was the highest for fungal infections,
intermediate for bacterial infections and the lowest for viral infec-
tions. Death associated with a fungal or bacterial infection
occurred between day 30 and 365 in 8 marrow recipients and no
blood stem cell recipient (p=0.02). In conclusion, blood stem cell
recipients have higher lymphocyte subset counts. This appears to
result in fewer infections.
DECREASED TRANSPLANT RELATED MORTALITY AFTER THYMO-
GLOBULINE CONDITIONING BEFORE BONE MARROW TRANSPLAN-
TATION USING UNRELATED DONORS. RESULTS FROM A MATCHED
COHORT STUDY
Remberger, M.1; Storer, B.2; Ringdén, O.1; Anasetti, C.2 1. Karolinska
Institutet, Stockholm, Sweden; 2. FHCRC, Seattle, WA
A single arm study was conducted at Huddinge to test the efﬁca-
cy of polyclonal rabbit antiserum speciﬁc for human T cells (Thy-
moglobulin) administered in vivo on days 1-5 before T-replete
unrelated donor marrow grafts in patients with leukemia (n=52)
for the prevention of graft-versus-Host Disease (GVHD) and
transplant-related mortality (TRM). A matched cohort of control
patients with similar characteristics and treated with a similar reg-
imen except for the omission of Thymoglobulin was identified
among those treated in Seattle during the same period 1993-98
(n=104). All patients received conditioning with cyclophos-
phamide and whole body irradiation, and GVHD prophylaxis
with cyclosporine and methotrexate. Median age was 27.5 (range
1-54) years for the study, and 33 (0.9-54) years for control
patients. Diagnosis was chronic myeloid leukaemia for 22 study
and 44 control patients, acute myeloid leukaemia for 14 study and
28 control patients, and acute lymphocytic leukaemia for 16 study
and 32 control patients. Stage and status of leukaemia at trans-
plantation was exactly balanced. Multivariable analyses were
adjusted for patient and donor age, HLA matching, patient and
donor CMV pre-transplant serology, donor gender, and marrow
cell dose. Non-relapse mortality was less in study patients (hazard
ratio = 0.05, 95% C.I. 0.008-0.3, p value = 0.001). The 5 year
cumulative incidence of non-relapse mortality was 21% in the
study cohort, and 37% in the control cohort. Overall mortality
was also less in study patients (hazard ratio 0.5, 95% C.I. 0.27-
0.97, p value = 0.04). Patients with chronic myeloid leukaemia in
chronic phase had a significantly higher risk of relapse in the
study cohort (p=0.04). Such difference was not seen in patients
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with acute leukaemia. These results suggest that outcome differ-
ences between the two patient cohorts might be due to the use of
Thymoglobulin.
QUALITY OF LIFE AND SEXUAL LIFE IN PATIENTS POST HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION
Park, E.; Lee, M.H.; Yoon, S.S.; Kim, W.S.; Park, C.; Samsung
Medical Center, Seoul, South Korea
The increasing number of survivors with HSCT face new health
issues regarding quality of life in recent years. HSCT with high
dose chemotherapy & TBI have a result of sexual dysfunction, fer-
tility and lower quality of life thereafter. As a result, 25% of
patients do not have sexual activity and almost all patients experi-
enced decreased quality of life.
The purpose of this study was to conﬁrm changing QOL and
sexual function of HSCT patients and to examine relationship
with QOL and sexual life and to present basic information which
can be helpful in counseling sexual problems and develop sexual
rehabilitation program.
The sample was composed of 38 respondents out of 44 patients
who had a sexual partner and had received stem cell transplanta-
tion between February 1994 and August 1999.
The results are as follows:
1. Scores of sexual satisfaction (p<0.005), sexual activity frequen-
cy p<0.001), sexual desire (p<0.01) and experienced orgasm
p<0.005) are signiﬁcantly decreased.
2. Overall sexual satisfaction score is decreased (pre s=10, post
s=3.25).
3. Patients physically experienced various changes.
4. The causes of avoidance of sexual activity were fatigue, anxi-
ety of the infection, decreased libido, and physical weakness.
5. Overall quality of life score is low (5.91) especially social
dimension score is 5.00 .
6. The related factors affected sexual activity were the quality of
life (DIFF 0.107), sex (0.213), age (0.248), duration (0.408).
Most patients experienced the decreasing quality of life, the
change of sexual life. And when physical weakness was added to
fatigue, the percentage of energy deﬁciency was up to 73.1%. But
physical dimension of quality of life is not significantly related
directly to sexual life.
In conclusion, teaching and counseling of sexual activity and
support to increase quality of life are necessary after transplanta-
tion. For this reason, more active and multiple nursing approaches
and practical counseling programs have to be developed.
SYNGENEIC STEM CELL TRANSPLANTATION FOR METASTATIC
BREAST CANCER
Williams, S.; Rizzo, D.; Wu, J.; Antman, K.; Writing Committee, B.
IBMTR, Milwaukee, WI
Metastatic breast cancer is a common indication for autologous
stem cell transplantation. Previous reports from the ABMTR have
shown the 3 year survival and progression free survival to be 31%
(95% CI, 28-34%) and 13% (10-16%), respectively. One potential
cause for high relapse rates is marrow contamination with tumor.
We describe 14 women with metastatic breast cancer transplanted
between 1991 and 1999 with stem cells from healthy identical
twins. Transplants were reported to the IBMTR by 13 centers.
Median age was 41y (range 34-50). 7 women had tumors express-
ing estrogen receptors; 12 were pre-menopausal at diagnosis.
Most(12 of 14) were treated with mastectomy, and all received
anthracycline-based regimens. Nine women received a taxane and
7 received radiotherapy. Three received hormonal therapy pre-
transplant. Two women received 1 chemotherapy regimen pre-
transplant, 5 had 2, 5 had 3, 1 had 4, and 1 had 5 regimens. The
median number of chemotherapy cycles pre-transplant was 8. The
median disease-free interval pre-transplant was 25 months. Per-
formance scores pre-transplant were 80% in 2, 90% in 10, and
100% in 2. Four women were in CR/CRU at transplant, 5 had a
PR, 2 had stable disease, and 2 were transplanted with progressive
disease. Induction of acute graft-versus-host disease (GVHD) was
attempted in 1, however no acute or chronic GVHD occurred. Six
women were treated with hormones, and 3 with radiation post-
transplant. 100-day treatment-related mortality was 7% (0-26%).
3-year survival was 63% (36-85%) and 3-year progression-free
survival was 17% (2-41%).
Although the number of patients is small, outcomes for women
transplanted with syngeneic grafts are similar to those of women
receiving autologous grafts. This suggests that residual cancer in
the patient is the major contributor to relapse after transplantation
for breast cancer.
